Evaluation of access and equity in the provision of medical abortion
Mifepristone, a safe and effective abortifacient, was included in the pharmaceutical benefits scheme in 2013, providing women in Australia with a non-surgical option for pregnancy termination. In the absence of national data on abortion, little is known about issues of accessibility to this service, and whether and how the availability of medical abortion impacts access. This collaborative study (with Marie Stopes International Australia) explores the prevalence of unwanted pregnancy in Australia, women's experiences of abortion, and the geographical distribution of medical abortion services.
- Angela Taft
- Mridula Shankar
- Jayne Lucke
- Kerry Petersen
- Julia Shelley, Deakin University
- Danielle Mazza, Monash University
- Kirsten Black, University of Sydney
- Philip Goldstone, MSH
- Safeera Hussainy, Monash University.
- La Trobe University
- Marie Stopes International Australia
- Women's Health Association of Victoria.
Data collection commenced in 2014.